Baseline characteristics
| Study | Group | Age (in years) | Sex (M/F) | Cirrhosis etiology | Child-Pugh score |
|---|---|---|---|---|---|
| Mostafa et al14 | Rifaximin | 55.8±4.81 | (90%/10%) | Hepatitis C | 10.25±1.1 |
| Norfloxacin | 56.5±4.17 | (88%/12%) | Hepatitis C | 10.67±1.8 | |
| Shamseya and Madkour15 | Rifaximin | 52.7±8.5 | (79.1%/20.9%) | Hepatitis C | 11.47±2.04 |
| Norfloxacin | 50.3±9.0 | (79.1%/20.9%) | Hepatitis C | 11.51±2.06 | |
| Assem et al16 | Rifaximin | 55±18 | (73.1%/26.9%) | Hepatitis C (90.2%) Others (9.7%) | 10.2±3.1 |
| Norfloxacin | 58±15 | (71.7%/28.3%) | Hepatitis C (93.6%) Others (6.4%) | 10.1±1.6 | |
| Elfert et al17 | Rifaximin | 53.78±7.52 | (74%/26%) | Data not available | Child B (44.3%) Child C (55.7%) |
| Norfloxacin | 54.12 ± 7.19 | (68%/32%) | Data not available | Child B (48.1%) Child C (51.9%) |